Skip to main content
SpringerLink
Log in

Interleukin-2 in Metastatic Renal Cell Carcinoma

  • Chapter
Renal Cell Carcinoma

Part of the book series: Current Clinical Oncology ((CCO))

  • 124 Accesses

Abstract

Interleukin-2 (IL-2) was first described as a T-cell growth factor (TCGF) in 1976 by Morgan et al. when it was noted that conditioned medium could support T-cell growth (1). IL-2 was later demonstrated to have no direct antitumor activity, but to mediate antitumor activity indirectly through the host immune response (2, 3). The primary source of IL-2 is from an antigen-stimulated TH1-type CD4+ T cell and, to a lesser extent, from activated CD8+ cells (4). At least two external signals are required for T-cell activation, one through the T-cell receptor complex (TCR/CD3+), and the second from an accessory cell expressing B7, a ligand for the T-cell CD28+ receptor. It is encoded on chromosome 4q26–28 (5) and was first cloned in 1983 (6). IL-2 is a 15 kD protein consisting of two paired α helices bound by an interchain di-sulfide bond between cysteine residues at positions 58 and 105. IL-2 interacts with the T-cell IL-2 Rβγ heterodimer at the receptor, the structure of which is similar to that of IL-4 and GM-CSF (7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Morgan DA, Ruscetti FW, and Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows, Science, 193 (1976) 1007–1008.

    Article  PubMed  CAS  Google Scholar 

  2. Young RC. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions ? N. Engl. J. Med., 338 (1998) 1305–1306.

    Article  PubMed  CAS  Google Scholar 

  3. Lafreniere R and Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2, Cancer Res., 45 (1985) 3735–3741.

    PubMed  CAS  Google Scholar 

  4. Rubin JT. Interleukin-2: its biology and clinical application in patients with cancer, Cancer Invest., 11 (1993) 460–472.

    Article  PubMed  CAS  Google Scholar 

  5. Siegel LJ, Harper ME, Wong-Staal F, et al. Gene for T cell growth factor: location on human chromosome 4q and feline chromosome BI, Science, 223 (1984) 175–178.

    Article  Google Scholar 

  6. Taniguchi T, Matsui H, Fuj ita T, et al. Structure and expression of a cloned cDNA for human interleukin2, Nature, 302 (1983) 305–310.

    Article  PubMed  CAS  Google Scholar 

  7. Bazan JF. Unraveling the structure of IL-2, Science, 257 (1992) 410–413.

    Article  PubMed  CAS  Google Scholar 

  8. Whittington R and Faulds D. Interleukin-2 a review of its pharmacological properties and therapeutic use in patients with cancer, Drugs, 46 (1993) 446–514.

    Article  PubMed  CAS  Google Scholar 

  9. Takeshita T, Asao H, Ohtani K, et al. Cloning of the γ chain of the human IL-2 receptor, Science, 257 (1992) 379–382.

    Article  PubMed  CAS  Google Scholar 

  10. Miyazaki T, Kawhara A, Fujii H, et al. Functional activation of Jak 1 and Jak 3 by selective association with IL-2 receptor subunits, Science, 266 (1994) 1045–1047.

    Article  PubMed  CAS  Google Scholar 

  11. Physicians’ Desk Reference, Medical Economics Co. Montvale, NJ, 1999, pp. 894–898.

    Google Scholar 

  12. Gearing AJH and Thorpe R. The international standard for human interleukin-2: calibration by international collaborative study, J. Immunol. Meth., 114 (1988) 3–9.

    Article  CAS  Google Scholar 

  13. Hank JA, Surfus J, Gan J, et al. Distinct clinical and laboratory activity of two recombinant interleukin2 preparations, Clin. Cancer Res., 5 (1999) 281–289.

    CAS  Google Scholar 

  14. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin2 produced in Escherichia coli, Science, 223 (1984) 1412–1415.

    Article  PubMed  CAS  Google Scholar 

  15. Lotze MT, Frana LW, Sharrow SO, et al. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin-2, J. Immunol., 134 (1985) 157–166.

    PubMed  CAS  Google Scholar 

  16. Yang JC and Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer, Cancer J. Sci. Am., 3 (1997) S79–S84.

    Google Scholar 

  17. Donohue JH and Rosenberg SA. The fate of interleukin-2 after in vivo administration, J. Immunol., 130 (1983) 2203–2208.

    PubMed  CAS  Google Scholar 

  18. Gibbons JA, Luo ZP, Hansen ER, et al. Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureter ligated rats, J. Pharmacol. Experiment. Therapeut., 272 (1995) 119–125.

    CAS  Google Scholar 

  19. Opphenheim M and Lotze MT. Interleukin-2: solid-tumor therapy, Oncology, 51 (1994) 154–169.

    Article  Google Scholar 

  20. Regulation of immune responses. In Cellular and Molecular Immunology. Abbas AK, Lichtman AH, and Pober JS (eds.), WB Saunders, Philadelphia, PA, 1997, pp. 213–230.

    Google Scholar 

  21. Jablons DE, Bolton E, Mertins S, et al. IL-2 based immunotherapy alters circulating neutrophil Fc expression and chemotaxis, J. Immunol., 144 (1990) 3630–3636.

    PubMed  CAS  Google Scholar 

  22. Ettinghausen SE and Rosenberg SA. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2, Cancer Res., 46 (1986) 2784–2792.

    PubMed  CAS  Google Scholar 

  23. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2 II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2, J. Immunol., 135 (1985) 2865–2875.

    PubMed  CAS  Google Scholar 

  24. Papa MZ, Mule JJ, and Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types, Cancer Res., 46 (1986) 4973–4978.

    PubMed  CAS  Google Scholar 

  25. Lotze MT, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer, Cancer, 58 (1986) 2764–2772.

    Article  PubMed  CAS  Google Scholar 

  26. Mule JJ, Shu S, Schwarz SL, and Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2, Science, 225 (1984) 1487–1489.

    Article  PubMed  CAS  Google Scholar 

  27. Mule JJ, Shu S, and Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo, J. Immunol., 135 (1985) 646–652.

    PubMed  CAS  Google Scholar 

  28. Lafreniere R and Rosenberg SA. Adoptive immunotherapy of murine hepatic metastasis with activated lymphokine killer (LAK) cells and recombinant IL-2 (RIL-s) can mediate regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma, J. Immunol., 135 (1985) 4273–4280.

    PubMed  CAS  Google Scholar 

  29. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastasis and subcutaneous tumor mediated by systemic administration of high-dose recombinant interleukin-2, J. Exp. Med., 161 (1985) 1169–1188.

    Article  PubMed  CAS  Google Scholar 

  30. Mazumder A, Eberlein TJ, Grimm EA, et al. Phase I study of adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells, Cancer, 53 (1984) 896–905.

    Article  PubMed  CAS  Google Scholar 

  31. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Engl. J. Med., 313 (1985) 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  32. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone, N. Engl. J. Med., 316 (1987) 889–897.

    Article  PubMed  CAS  Google Scholar 

  33. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, Annals Surg., 210 (1989) 474–485.

    Article  CAS  Google Scholar 

  34. Yang JC. Of snails and holy grails, Cancer J. Sci. Am., 3 (1997) S142–S143.

    Google Scholar 

  35. Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells, Ann. Int. Med., 108 (1988) 518–523.

    Article  PubMed  CAS  Google Scholar 

  36. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer, N. Engl. J. Med., 316 (1987) 898–905.

    Article  PubMed  CAS  Google Scholar 

  37. Gaynor ER, Weiss GR, Margolin KA, et al. Phase I study of high dose continuous infusion interleukin2 and autologous lymphokine activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma, J. Natl. Cancer Inst., 82 (1990) 1397–1402.

    Article  PubMed  CAS  Google Scholar 

  38. Parkinson DR, Fisher RI, Rayner AA, et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen, J. Clin. Oncol., 8 (1990) 1630–1636.

    PubMed  CAS  Google Scholar 

  39. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma, J. Clin. Oncol., 10 (1992) 275–281.

    PubMed  CAS  Google Scholar 

  40. Dillman RO, Church CC, Oldham RK, West WH, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer, Cancer, 71 (1993) 2358–2370.

    Article  PubMed  CAS  Google Scholar 

  41. Rosenberg SA, Lotze MT, Yang JC, et al, Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer, J. Natl. Cancer Inst., 85 (1993) 622–632.

    Article  PubMed  CAS  Google Scholar 

  42. McCabe MS, Stablein D, and Hawkins MJ. The modified group C experience—Phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma, Proc. Am. Soc. Clin. Oncol., 10 (1991) a213.

    Google Scholar 

  43. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma, Cancer, 76 (1995) 824–832.

    Article  PubMed  CAS  Google Scholar 

  44. Abrams JS, Rayner AA, Wiernik PH, et al. High dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma, J. Natl. Cancer Inst., 82 (1990) 1202–1206.

    Article  PubMed  CAS  Google Scholar 

  45. Bukowski RM, Goodman P. Crawford ED, et al. Phase II trial of high-dose intermittent interleukin2 in metastatic renal cell carcinoma: a Southwest Oncology Group Study, J. Natl. Cancer Inst., 82 (1990) 143–146.

    Article  PubMed  CAS  Google Scholar 

  46. Oleksowicz L, Dutcher JP, et al. A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma, J. Cancer Res. Clin. Oncol., 125 (1999) 101–108.

    Article  PubMed  CAS  Google Scholar 

  47. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J. Clin. Oncol., 13 (1995) 688–696.

    PubMed  CAS  Google Scholar 

  48. Fisher RI, Rosenberg SA, Sznol M, et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update, Cancer J. Sci. Am., 3 (1997) S70–S72.

    Google Scholar 

  49. Atkins MR and Dutcher JP. Renal-cell carcinoma, N. Engl. J. Med., 336 (1997) 809.

    Article  PubMed  CAS  Google Scholar 

  50. Lissoni P. Effects on low-dose recombinant interleukin-2 in human malignancies, Cancer J. Sci. Am., 3 (1997) S115–S120.

    Google Scholar 

  51. Stadler WM and Vogelzang NJ. Low dose interleukin-2 in the treatment of metastatic renal cell carcinoma, Semin. Oncol., 22 (1995) 67–73.

    Google Scholar 

  52. Whitehead RP, Ward D, Hemingway L, et al. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma, Cancer Res., 50 (1990) 6708–6715.

    PubMed  CAS  Google Scholar 

  53. Stein RC, Malkovska V, Morgan S, et al. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin 2, Br. J. Cancer, 63 (1991) 275–278.

    Article  PubMed  CAS  Google Scholar 

  54. Buter J, Sleifer DT, van der Graff WTA, et al. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2, Semin. Oncol., 20 (1993) 16–21.

    CAS  Google Scholar 

  55. Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report, J. Clin. Oncol., 12 (1994) 1572–1576.

    PubMed  CAS  Google Scholar 

  56. Rosenberg SA, Spiess P, and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science, 223 (1986) 1318–1321.

    Article  Google Scholar 

  57. Topalian SL, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study, J. Clin. Oncol., 6 (1988) 839–853.

    PubMed  CAS  Google Scholar 

  58. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma, J. Clin. Oncol., 17 (1999) 2521–2529.

    PubMed  CAS  Google Scholar 

  59. Lotze MT, Line BR, Mathisen DJ, et al. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors, J. Immunol., 125 (1980) 1487–1493.

    PubMed  CAS  Google Scholar 

  60. Weber JS and Rosenberg SA. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro, Cancer Res., 48 (1988) 5818–5824.

    PubMed  CAS  Google Scholar 

  61. Rubin JT, Elwood LT, Rosenberg SA, et al. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans, Cancer Res., 49 (1989) 7086–7092.

    PubMed  CAS  Google Scholar 

  62. Cameron RB, McIntosh JK, and Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid á-interferon in the treatment of established murine hepatic metastases, Cancer Res., 48 (1988) 5810–5817.

    PubMed  CAS  Google Scholar 

  63. Rosenberg SA, Lotze MY, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer, J. Clin. Oncol., 7 (1989) 1863–1874.

    PubMed  CAS  Google Scholar 

  64. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma, J. Clin. Oncol., 11 (1993) 661–670.

    PubMed  CAS  Google Scholar 

  65. Lissoni P, Barni S, Ardizzola A, et al. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma, Tumori, 79 (1993) 397–400.

    PubMed  CAS  Google Scholar 

  66. Negier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma, N. Engl. J. Med., 338 (1998) 1272–1278.

    Article  Google Scholar 

  67. Lissoni P, Barni S, Ardizzoia A, et al. Second line therapy with low-dose subcutaneous interleukin2 alone in advanced renal cancer patients resistant to interferon-alpha, Eur. J. Cancer, 28 (1992) 92–96.

    Article  PubMed  CAS  Google Scholar 

  68. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment ? J. Clin. Oncol., 17 (1999) 2039–2043.

    PubMed  CAS  Google Scholar 

  69. Huland E, Heinzer H, Mir TS, et al. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years experience, Cancer J. Sci. Am., 3 (1997) S98–S105.

    Google Scholar 

  70. Sherry RM, Rosenberg SA, and Yang JC. Relapse after response to interleukin-2 based immunotherapy: patterns of progression and response to retreatment, J. Immunother., 10 (1991) 371–375.

    Article  PubMed  CAS  Google Scholar 

  71. Buter J, Janssen RAJ, Mulder NH, et al. Recombinant interleukin 2 for metastatic renal cell carcinoma in haemodialysis patients, Eur. J. Cancer, 28A (1992) 1770–1771.

    Article  Google Scholar 

  72. Suc E, Neuville S, Lacombe JL, et al. Interleukin-2 in a haemodialysis patient with metastatic renal cell cancer, Presse Med., 24 (1995) 327.

    PubMed  CAS  Google Scholar 

  73. Joffe JK, Banks RE, Forbes MA, et al. A phase II study on interferon á, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation, Br. J. Urol., 77 (1996) 638–649.

    Article  PubMed  CAS  Google Scholar 

  74. Banks RE, Forbes MA, Hallam S, et al. Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines, Br. J. Urol., 75 (1997) 1842–1848.

    CAS  Google Scholar 

  75. Numerof RP, Aronson FR, Mier JW, et al. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells, J. Immunol., 141 (1988) 4250–4257.

    PubMed  CAS  Google Scholar 

  76. Smith KA. Rational interleukin-2 therapy, Cancer J. Sci. Am., 3 (1997) S137–S 140.

    Google Scholar 

  77. Mier JW, Vachino G, Klernpner MS, et al. Inhibition of interleukin-2 induced tumor necrosis factor release by dexamethasone: Prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2 associated side effects, Blood, 76 (1990) 1933–1940.

    PubMed  CAS  Google Scholar 

  78. Heslop HE, Gottlieb DJ, Bianchi AC, et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation, Blood, 74 (1989) 1374–1380.

    PubMed  CAS  Google Scholar 

  79. Ochoa JB, Curti B, Peitzman AB, et al. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes, J. Natl. Cancer Inst., 84 (1992) 864–867.

    Article  PubMed  CAS  Google Scholar 

  80. Jansson OT, Morcos E, Brundin L, et al. Nitric oxide synthase activity in human renal cell carcinoma, J. Urol., 160 (1998) 556–560.

    Article  PubMed  CAS  Google Scholar 

  81. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2, J. Clin. Oncol., 7 (1989) 7–20.

    PubMed  CAS  Google Scholar 

  82. Margolin KA, Raynor AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines, J. Clin. Oncol., 7 (1989) 486–498.

    PubMed  CAS  Google Scholar 

  83. Shalmi CL, Dutcher JP, Feinfeld DA, et al. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion, J. Clin. Oncol., 8 (1990) 1839–1846.

    PubMed  CAS  Google Scholar 

  84. Fisher B, Keenan AM, Garra BS, et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients, J. Clin. Oncol., 7 (1989) 1852–1862.

    PubMed  CAS  Google Scholar 

  85. Ettinghausen SE, Puri RK, Rosenberg SA, et al. Increased vascular permeability in organs mediated by systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice, J. Natl. Cancer Inst., 80 (1988) 177–188.

    Article  PubMed  CAS  Google Scholar 

  86. Gaspari AA, Lotze MT, Rosenberg SA, et al. Dermatologic changes associated with interleukin 2 administration, JAMA, 258 (1987) 1624–1629.

    Article  PubMed  CAS  Google Scholar 

  87. Staunton MR, Scully MC, LeBoit PE, et al. Life threatening bullous skin eruptions during interleukin2 therapy, J. Natl. Cancer Inst., 83 (1991) 56–57.

    Article  PubMed  CAS  Google Scholar 

  88. Lotze MT and Rosenberg SA. Interleukin-2: clinical applications. In Biologic Therapy of Cancer. DeVita VT, Hellman S, and Rosenberg SA (eds.), JB Lippincott, Philadelphia, PA, 1991, pp. 159–177.

    Google Scholar 

  89. Weijl NI, Van Der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment, J. Clin. Oncol., 11 (1993) 1376–1383.

    PubMed  CAS  Google Scholar 

  90. Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone, J. Immunother., 18 (1996) 272–278.

    Article  Google Scholar 

  91. Ettinghausen SE, Moore JG, White DE, et al. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients, Blood, 69 (1987) 1654–1660.

    PubMed  CAS  Google Scholar 

  92. Schaafsma MR, Fibbe WE, Van Der Harst D, et al. Increased numbers of circulating hematopoietic progenitor cells after treatment with high dose interleukin-2 in cancer patients, Br. J. Haematol., 76 (1990) 180–185.

    Article  PubMed  CAS  Google Scholar 

  93. Gottlieb DJ, Prentice HG, Heslop He, et al. IL-2 infusion abrogates humoral immune responses in humans, Clin. Experiment. Immunol., 87 (1992) 493–498.

    Article  CAS  Google Scholar 

  94. Hartmann LC, Urba WJ, Steiss RJ, et al. Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2 treated patients, J. Natl. Cancer Inst., 81 (1989) 1190–1193.

    Article  PubMed  CAS  Google Scholar 

  95. Bock SN, Lee RE, Fisher B, et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy, J. Clin. Oncol., 8 (1990) 161–169.

    PubMed  CAS  Google Scholar 

  96. Pockaj BA, Topalian SL, Steinberg SM, et al. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses, J. Clin. Oncol., 11 (1993) 136–147.

    PubMed  CAS  Google Scholar 

  97. Fishman JE, Aberle DR, Moldawer NP, et al. Atypical contrast reactions associated with systemic interleukin-2 therapy, AJR, 156 (1991) 833–834.

    Article  PubMed  CAS  Google Scholar 

  98. Shulman KL, Thompson JA, Benyunes MC, et al. Adverse reactions to intravenous contrast media in patients treated with interleukin-2, J. Immunother., 13 (1993) 208–212.

    Article  CAS  Google Scholar 

  99. Philip T, Negrier S, Lasset C, et al. Patients with metastatic RCC candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients, Br. J. Cancer, 68 (1993) 1036–1042.

    Article  PubMed  CAS  Google Scholar 

  100. Palmer PA, Atzpodien J, Philip T, et al. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced RCC, Cancer Biother., 8 (1993) 123–136.

    Article  PubMed  CAS  Google Scholar 

  101. Whitehead RP, Wolf MK, Solanki DL et al. A phase II trial of continuous infusion recombinant interleukin-2 in patients with advanced RCC: a Southwest Oncology Group study, J. Immunother., 18 (1995) 104–114.

    Article  CAS  Google Scholar 

  102. Escudier B, Farace F, Theodore C, et al. Traitment du cancer du rein metastatique avec un nouveau schema d’interleukine-2: experience de l’institut Gustave-Roussy, Bull. Cancer (Paris), 82 (1995) 296–302.

    CAS  Google Scholar 

  103. Lopez M, Carpano S, Cancrini, A, et al. Phase II study of continuous infusion of recombinant interleukin-2 in patients with advanced RCC, Ann. Oncol., 4 (1993) 689–691.

    PubMed  CAS  Google Scholar 

  104. Escudier B, Ravaud A, Fabbro M, et al. High-dose interleukin-2 two days a week for metastatic RCC: a FNCLCC multicenter study, J. Immunother., 16 (1994) 306–312.

    Article  CAS  Google Scholar 

  105. von der Maase H, Geertsen P, Thatcher N, et al. Recombinant interleukin-2 in metastatic RCC: a European multicentre phase II study, Eur. J. Cancer, 27 (1991) 1583–1589.

    Article  PubMed  CAS  Google Scholar 

  106. Koretz MJ, Lawson DH, York RM, et al. Randomized study of interleukin-2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer, Arch. Surg., 126 (1991) 898–903.

    CAS  Google Scholar 

  107. Geertsen PF, Hermann GG, von der Maase H, et al. Treatment of metastatic RCC by intermittent continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study, J. Clin. Oncol., 10 (1992) 753–759.

    PubMed  CAS  Google Scholar 

  108. Stoter G, Fossa SD, Rugarli C, et al. Metastatic renal cell cancer treated with low-dose interleukin-2. A phase II multicenter study, Cancer Treat Rev., 16 (Suppl A) (1989) 111–113.

    Article  PubMed  Google Scholar 

  109. Negrier S, Escudier B, Lasset C, et al. The FNCLCC Crecy trial: interleukin 2 (IL2) + interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC), Proc. ASCO, 15 (1996) 248.

    Google Scholar 

  110. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2, JAMA, 271 (1994) 907–913.

    Article  PubMed  CAS  Google Scholar 

  111. Tanej a SS, Pierce W, Figlin R, et al. Immunotherapy for RCC: the era of interleukin-2 based treatment, Urology, 45 (1995) 911–924.

    Article  CAS  Google Scholar 

  112. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma, Cancer, 80 (1997) 1198–1220.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Thomas Olencki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald M. Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Experimental Therapeutics, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    Ronald M. Bukowski MD (Director) (Director)

  2. Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA

    Andrew C. Novick MD (Chairman) (Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Olencki, T., Bukowski, R.M. (2000). Interleukin-2 in Metastatic Renal Cell Carcinoma. In: Bukowski, R.M., Novick, A.C. (eds) Renal Cell Carcinoma. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-229-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-229-6_19

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6401-7

  • Online ISBN: 978-1-59259-229-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation